Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of TREMFYA^®(guselkumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Johnson & Johnson announced the submission of a supplemental Biologics License Application to the US FDA seeking approval of TREMFYA® for treatment of adults with moderately to severely active ulcerative colitis.